No Data
Zhangzhou pientzehuang pharmaceutical "curved" acquisition of Fujian cosunter pharmaceutical? The innovative drugs sector sees the reappearance of traditional chinese medicine industry players | Read the announcement quickly.
Fujian Cosunter Pharmaceutical announced that the Yuanshan Fund intends to become a shareholder with more than 5% stake in the company through a transfer payment of nearly 0.2 billion yuan. The partners of the Yuanshan Fund consist of a wholly state-owned company and a wholly-owned subsidiary of zhangzhou pientzehuang pharmaceutical, among which the investment from zhangzhou pientzehuang pharmaceutical is the largest limited partner in the fund.
China's Retail Turnover Rise to Eight-month High in Oct; Jobless Rate Fell to Four-month Low
"Going global" and "innovation" are the key words that cannot be bypassed. Sun Piaoyang from Jiangsu Hengrui Pharmaceuticals, Zhu Yi from Baheal Pharm and other top pharmaceutical industry leaders jointly discuss the next decade | Industry Observation
On November 14, 2024, the opening ceremony of the Insight Conference was held in Chengdu, where experts in the pharmaceutical industry, investors, and chairmen of top listed companies exchanged views on the challenges and opportunities facing the China meheco group. The two key themes of "going global" and "innovation" ran through the entire conference. Faced with the question of the future direction of innovative drugs in China, various enterprises also provided different answers.
Hillhouse HHLR Q3 hold positions: Chinese concept stocks hold an absolute dominant position, and the total market value of hold positions grew by more than 10%!
①HHLR Advisors, a subsidiary of Hillhouse Capital, saw its total market cap of US stocks holding positions grow by over 10% in the third quarter, with 9 of the top ten heavy positions being Chinese concept stocks; ②HHLR Advisors continued to hold heavy positions in Chinese concept stocks in the third quarter, with the market cap of Chinese concept stocks increasing from 85% in the second quarter to 93% in the third quarter.
Asia Markets Mixed, Mirroring Global Market Sentiments as Investors Assess Latest U.S. CPI Figures
BeiGene Analyst Ratings